Cover Image
市場調查報告書

Yungjin Pharm. Co., Ltd.:產品平台分析

Yungjin Pharm. Co., Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256065
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Yungjin Pharm. Co., Ltd.:產品平台分析 Yungjin Pharm. Co., Ltd. - Product Pipeline Review - 2016
出版日期: 2016年07月20日 內容資訊: 英文 39 Pages
簡介

Yungjin Pharm. Co., Ltd. ha,是總公司設立於韓國的製藥企業,正在開發·製造並銷售API(醫藥品有效成分),處方藥,強壯飲料等。API方面提供以頭孢菌素為首的產品,處方藥方面提供抗菌劑,中樞神經系統疾病,心血管系統疾病,內分泌系疾病等各種領域的產品。

本報告提供Yungjin Pharm. Co., Ltd. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Yungjin Pharm. Co., Ltd. 的基本資料

  • Yungjin Pharm. Co., Ltd. 概要
  • 主要資訊
  • 企業資料

Yungjin Pharm. Co., Ltd. :R&D概要

  • 主要的治療範圍

Yungjin Pharm. Co., Ltd. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Yungjin Pharm. Co., Ltd. :開發中產品概況

  • 後期階段產品開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Yungjin Pharm. Co., Ltd. :藥物簡介

  • KTG-001
  • (acetaminophen + tramadol hydrochloride) SR
  • YPL-001
  • YBH-1603
  • YNP-1707
  • YOB-1604
  • ceftaroline fosamil
  • YAR-1502
  • YHT-1808
  • YLS-1501
  • YPU-1705
  • YRA-1909
  • YGD-1710
  • YPE-1706

Yungjin Pharm. Co., Ltd. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Yungjin Pharm. Co., Ltd. :開發暫停中的計劃

Yungjin Pharm. Co., Ltd. :總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08095CDB

Summary

Global Markets Direct's, 'Yungjin Pharm. Co., Ltd. - Product Pipeline Review - 2016', provides an overview of the Yungjin Pharm. Co., Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Yungjin Pharm. Co., Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Yungjin Pharm. Co., Ltd.
  • The report provides overview of Yungjin Pharm. Co., Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Yungjin Pharm. Co., Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Yungjin Pharm. Co., Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Yungjin Pharm. Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Yungjin Pharm. Co., Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Yungjin Pharm. Co., Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Yungjin Pharm. Co., Ltd. Snapshot
    • Yungjin Pharm. Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Yungjin Pharm. Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Yungjin Pharm. Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • Yungjin Pharm. Co., Ltd. - Pipeline Products Glance
    • Yungjin Pharm. Co., Ltd. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Yungjin Pharm. Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Yungjin Pharm. Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Yungjin Pharm. Co., Ltd. - Drug Profiles
    • (acetaminophen + tramadol hydrochloride) SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YBH-1603
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YPL-001
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YNP-1707
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YOB-1604
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ceftaroline fosamil
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YLS-1501
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YRA-1909
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YSA-2021
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YAC-1912
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YMS-1716
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YPC-1811
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YPP-2022
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • YTD-2020
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Yungjin Pharm. Co., Ltd. - Pipeline Analysis
    • Yungjin Pharm. Co., Ltd. - Pipeline Products by Target
    • Yungjin Pharm. Co., Ltd. - Pipeline Products by Route of Administration
    • Yungjin Pharm. Co., Ltd. - Pipeline Products by Molecule Type
    • Yungjin Pharm. Co., Ltd. - Pipeline Products by Mechanism of Action
  • Yungjin Pharm. Co., Ltd. - Dormant Projects
  • Yungjin Pharm. Co., Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Yungjin Pharm. Co., Ltd., Key Information
  • Yungjin Pharm. Co., Ltd., Key Facts
  • Yungjin Pharm. Co., Ltd. - Pipeline by Indication, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline by Stage of Development, 2016
  • Yungjin Pharm. Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Yungjin Pharm. Co., Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Yungjin Pharm. Co., Ltd. - Pre-Registration, 2016
  • Yungjin Pharm. Co., Ltd. - Phase III, 2016
  • Yungjin Pharm. Co., Ltd. - Phase II, 2016
  • Yungjin Pharm. Co., Ltd. - Phase I, 2016
  • Yungjin Pharm. Co., Ltd. - Preclinical, 2016
  • Yungjin Pharm. Co., Ltd. - Discovery, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline by Target, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline by Route of Administration, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline by Molecule Type, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Yungjin Pharm. Co., Ltd. - Dormant Developmental Projects,2016

List of Figures

  • Yungjin Pharm. Co., Ltd. - Pipeline by Top 10 Indication, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline by Stage of Development, 2016
  • Yungjin Pharm. Co., Ltd. - Monotherapy Products in Pipeline, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline by Target, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline by Route of Administration, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline by Molecule Type, 2016
  • Yungjin Pharm. Co., Ltd. - Pipeline Products by Mechanism of Action, 2016
Back to Top